PCT for SARMs: Suppression, Timing and What the Evidence Shows

PCT for SARMs (post cycle therapy) refers to the drugs some users take after a SARM cycle to help their own testosterone production restart. It exists because SARMs are not hormonally neutral. In controlled trials, even small doses of LGD-4033 and ostarine lowered total testosterone, and the doses people take outside of trials are usually several times higher. Whether a given person needs PCT depends on how far their hormones actually dropped, which only bloodwork can show.

No clinical trial has tested PCT after SARM use specifically. The drugs involved (tamoxifen, clomiphene, enclomiphene and hCG) are prescription medications that doctors use off-label for secondary hypogonadism, including hypogonadism after anabolic steroid use. This article covers what the research shows about SARMs suppression, what protocols are commonly reported in user communities, and where the evidence stops.

Muscle & Brawn is an independent news and information publication. We publish, we do not sell, and we do not encourage the use of SARMs or anabolic steroids.

Do You Need PCT After SARMs?

The short answer from the evidence is that most SARM cycles at commonly reported doses will lower testosterone, but not every cycle causes the kind of shutdown that requires drug-assisted recovery. The original marketing pitch for SARMs was that they built muscle without shutting down the “test factory.” The trial data does not support that.

Two human studies show the pattern clearly:

• LGD-4033 (ligandrol). Basaria and colleagues gave 76 healthy young men placebo or 0.1, 0.3 or 1.0 mg of LGD-4033 daily for 21 days. Total testosterone, SHBG, HDL and triglycerides fell in a dose-dependent way. Free testosterone and FSH dropped significantly at the 1 mg dose. Hormones and lipids returned to baseline after the drug was stopped, during a five-week follow-up.
• Ostarine (enobosarm, GTx-024). In a 12-week phase II trial in older men and postmenopausal women, men taking 1 mg and 3 mg a day saw total testosterone fall by roughly 6 to 7 nmol/L, and SHBG fell significantly at 3 mg. Free testosterone, LH and FSH did not change significantly in men at those doses, and HDL dropped 17% at 1 mg and 27% at 3 mg.

Two points matter when reading these studies. First, the trial doses were small. User communities commonly report 5-10 mg of LGD-4033 and 10-25 mg of ostarine, which is several times higher than anything tested, and cycles of 8-12 weeks rather than 3. Second, both trials showed recovery without any PCT, but that was after low doses and short exposure. Nobody has measured how long recovery takes after the higher doses and longer cycles that are typical outside research settings.

A 2021 survey of 343 SARM users recruited through Reddit found that more than half reported side effects, including reduced testicle size and mood swings, and more than 90% had not consulted a physician. A 2025 systematic review of SARM use in athletes listed testosterone suppression among the consistent findings across clinical and preclinical studies.

So the honest answer to “do you need PCT after SARMs” is that it depends on the compound, dose, cycle length and the person, and that bloodwork after the cycle is the only way to know whether testosterone is recovering on its own.

How SARMs Suppression Works

SARMs (selective androgen receptor modulators) bind the androgen receptor. They were designed to act more strongly in muscle and bone than in the prostate, but the brain also reads androgen receptor activity. When the hypothalamus and pituitary sense more androgen signaling, they cut GnRH, LH and FSH. Less LH means the testes make less testosterone. Less FSH means sperm production can fall.

This is the same feedback loop that steroids shut down, and it is why the claim that SARMs “are not androgenic” is wrong. They are androgen receptor agonists by definition. Users report androgenic side effects such as acne and hair shedding, and the FDA lists testicular shrinkage, infertility and sexual dysfunction among the problems associated with SARMs.

SARMs also lower SHBG, the protein that carries testosterone in the blood. That matters when reading bloodwork. A low total testosterone reading after a cycle can partly reflect low SHBG, which is why free testosterone and LH give a clearer picture than total testosterone alone. See our free testosterone range guide.

What About Estrogen?

A common claim is that SARMs raise estrogen through aromatization. That is not correct for nonsteroidal SARMs such as ostarine, LGD-4033 and RAD-140. They are not substrates for the aromatase enzyme, so they do not convert to estradiol.

What actually happens is the reverse. When a SARM suppresses natural testosterone, there is less testosterone available to convert to estradiol, so estradiol often falls. Low estradiol in men is linked to low libido, joint discomfort and low mood, symptoms some users misread as high estrogen and treat with aromatase inhibitors.

There are two exceptions:

• YK-11 is chemically a steroid (a 19-norpregnane derivative), not a nonsteroidal SARM, and it has no human safety or pharmacology data. In cell studies it acts as a partial androgen receptor agonist and raises follistatin.
• Mislabeled products. In a JAMA analysis of 44 products sold online as SARMs, only 52% contained a SARM at all, 25% contained substances not on the label, and only 41% matched the labeled dose. A product contaminated with a steroid or prohormone can produce estrogenic side effects that a pure nonsteroidal SARM would not.

SARMs Suppression Levels, Half-Lives and Evidence

Suppression level is the main factor that decides whether PCT for SARMs is discussed at all. The table below summarizes the suppression commonly reported for each compound in user communities alongside the published evidence. The “reported suppression” column reflects user reports and bloodwork shared online, not controlled data, and suppression in any individual depends heavily on dose and duration.

MK-677 (a growth hormone secretagogue) and cardarine (a PPAR-delta agonist) are often sold alongside SARMs but are not SARMs. Neither works through the androgen receptor, so neither suppresses testosterone the way SARMs do, and neither is a reason for PCT for SARMs on its own.

Half-life matters for timing. A drug takes roughly five half-lives to clear. For ostarine or LGD-4033 that is about five to seven days. For RAD-140, with its measured half-life of 44.7 hours, that is closer to nine or ten days. The commonly reported practice of starting PCT within two or three days of the last dose comes from user communities, not from pharmacokinetic data, and it means some of the SARM is still active when the SERM begins.

How SARMs PCT Is Commonly Reported

PCT for SARMs borrows its drugs from steroid PCT. None of them is approved for this purpose. The evidence for how they work comes from clinical use in men with secondary hypogonadism (low testosterone caused by a lack of LH and FSH signal) and from reviews of steroid-induced hypogonadism, where no high-quality trials exist. A 2026 narrative review of clomiphene in post cycle therapy described it as the most commonly used off-label drug in this setting, with consistent improvements in hormone levels but poorly defined safety and monitoring standards.

The Drugs Involved

• Tamoxifen (Nolvadex). A SERM that blocks estrogen feedback at the hypothalamus and pituitary, which raises LH and FSH. It is the drug most often reported for SARMs PCT. See our Nolvadex PCT guide for its full profile.
• Clomiphene (Clomid). A SERM with a stronger effect on LH and FSH. Its zuclomiphene isomer has a long half-life and is linked to mood changes and, less often, visual disturbances. Our Clomid guide covers both.
• Enclomiphene. The active isomer of clomiphene without zuclomiphene. In a randomized trial in men with secondary hypogonadism, enclomiphene raised testosterone while preserving sperm counts, unlike topical testosterone. It is not FDA-approved as a standalone drug. Our enclomiphene guide covers the research.
• hCG. Acts like LH directly on the testes. It is rarely reported for SARM cycles and is mostly discussed for long or heavy steroid cycles. See our hCG for bodybuilding guide.

Protocols Commonly Reported in User Communities

The protocols below are what users and forum guides commonly describe. They are not clinically tested for SARMs, they are not recommendations, and Muscle & Brawn does not suggest that anyone follow them. They are reported here so readers can compare them with the evidence.

These mirror the light steroid protocols in our best PCT cycle guide, but SARMs PCT has no outcome data of its own.

Reported Side Effects of PCT Drugs

Clomiphene is most often linked to mood swings, emotional sensitivity and visual symptoms. Tamoxifen is linked to hot flushes, nausea and headaches, and carries a known clotting risk in clinical use. hCG can cause injection site pain and raise estradiol. PCT drugs also do not get a free pass on the liver. In two published cases, young men developed cholestatic liver injury after stopping ligandrol and/or ostarine while on PCT, and the authors pointed to unknown substances used for PCT, high doses and no monitoring as contributing factors.

When PCT for SARMs Starts After a Cycle

Timing is where user practice and pharmacology part ways in PCT for SARMs. Forum guides commonly say to start PCT the day after the last dose or within two to three days. The reasoning is that SARMs have shorter half-lives than injectable steroid esters, which is only partly true. Andarine clears fast, but LGD-4033 has a long elimination half-life, and RAD-140’s measured half-life of 44.7 hours means meaningful drug levels remain for over a week. A SERM started while the SARM is still active is competing with ongoing suppression.

Some guides also repeat the rule of “time on equals time off,” meaning a break at least as long as the cycle. This is a community convention, not a finding from research. Recovery time in the LGD-4033 trial was measured in weeks after a 21-day, low-dose exposure. There is no data for recovery after an 8-12 week cycle at five to ten times that dose.

Men coming off anabolic steroids can stay hypogonadal for months. SARMs are generally reported as less suppressive than steroids, but stacking compounds or running back-to-back cycles narrows that gap.

Bloodwork for SARMs PCT: What to Test and When

Bloodwork is the only objective way to see whether a SARM cycle caused suppression, whether PCT for SARMs is warranted at all, and whether recovery is happening. Clinicians who see patients after SARM or steroid use typically look at three groups of markers.

Hormones

• Total testosterone and free testosterone
• LH and FSH (low or undetectable values point to central suppression)
• SHBG (SARMs lower it, which skews total testosterone)
• Estradiol, ideally a sensitive LC-MS/MS assay rather than a standard immunoassay

Liver

• ALT and AST
• Bilirubin and alkaline phosphatase (SARM liver injury is often cholestatic, so bilirubin can rise sharply)

Cardiometabolic

• Lipid panel, especially HDL, which fell in both the ostarine and LGD-4033 trials
• Complete blood count, including hematocrit

Timing commonly used

If LH, FSH and testosterone are still low two to three months after stopping, that is a medical issue, not a forum issue. A doctor can test for persistent secondary hypogonadism and treat it with monitoring.

Liver, Lipids and Other Risks PCT Does Not Fix

SARMs are often marketed as a safer alternative to steroids that “don’t negatively impact health markers,” and RAD-140 is sometimes described as having no liver risk. Both claims are wrong.

Liver injury. Published case reports of drug-induced liver injury now cover several SARMs. RAD-140 has been linked to severe and cholestatic liver injury in multiple reports. LGD-4033 has its own case reports, and a 52-year-old man developed liver injury after taking products containing both RAD-140 and LGD-4033, with liver enzymes taking about three months to normalize after he stopped. In the RAD-140 phase 1 trial, elevated AST and ALT were the most common adverse events. Jaundice, dark urine, itching and fatigue are the warning signs described in these reports.

Lipids. HDL fell 17-27% in the ostarine trial and dropped dose-dependently in the LGD-4033 trial. The FDA lists a higher risk of heart attack and stroke among the concerns with SARMs.

Regulatory status. No SARM is approved by the FDA for any use. The FDA began warning companies in 2017 that SARMs sold as supplements are unapproved drugs, and its 2023 consumer update lists liver injury and acute liver failure, heart attack and stroke, psychosis, infertility and testicular shrinkage among the associated problems. Our are SARMs legal guide covers the legal picture by country.

Sport. SARMs are prohibited at all times under section S1.2 (other anabolic agents) of the WADA Prohibited List. Tamoxifen, clomiphene and enclomiphene are also prohibited under S4 (hormone and metabolic modulators). PCT does not make a tested athlete’s cycle any less detectable.

PCT for SARMs addresses one problem, the drop in natural testosterone. It does not reverse liver strain, restore HDL or remove contaminants from a mislabeled product.